dr. davids on the potential utility of ibrutinib/umbralisib in mcl and cll
Published 4 years ago • 46 plays • Length 1:07Download video MP4
Download video MP3
Similar videos
-
0:47
dr. davids on the potential utility of frontline ibrutinib/umbralisib in mcl and cll
-
0:47
dr. davids on remaining questions with umbralisib/ibrutinib in cll and mcl
-
1:22
dr. davids on updated data with ibrutinib/umbralisib in r/r cll and mcl
-
1:22
dr. davids on rationale for ibrutinib/umbralisib combo in r/r cll and mcl
-
2:34
dr. davids on the combination of ibrutinib and obinutuzumab in cll
-
9:02
efficacy and future role of ibrutinib in cll and mcl
-
1:51
long-term results of ibrutinib/umbralisib show efficacy in cll and mcl
-
1:44
ibrutinib and fcr in cll irrespective of ighv mutation status
-
7:01
novel frontline combinations with ibrutinib in cll
-
1:05
dr. smith on using venetoclax versus ibrutinib in cll
-
1:22
dr. lee on cirmtuzumab/ibrutinib dosing in mcl and cll
-
0:57
dr. byrd on alacabrutinib's mechanism of action in cll
-
1:29
dr. james on update of ibrutinib for chronic lymphocytic leukemia
-
1:06
dr. shah on options for ibrutinib-intolerant patients with mcl
-
1:17
dr. davids on ibrutinib plus fcr in younger patients with cll
-
1:09
dr. davids discusses the results of ibrutinib plus fcr in cll
-
3:33
dr. matthew davids on advances in cll treatment | dana-farber cancer institute
-
1:10
dr. hamlin on toxicities associated with ibrutinib and buparlisib in mcl, fl, and dlbcl
-
1:03
dr. maddocks on the role of zanubrutinib in b-cell malignancies